PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis

BACKGROUND: Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1) <50%. Although single-agent pembrolizumab has also demonstrated some activity in this setting, no reliable biomarkers yet exist for se...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Russo, Giuseppe, Prelaj, Arsela, Dolezal, James, Beninato, Teresa, Agnelli, Luca, Triulzi, Tiziana, Fabbri, Alessandra, Lorenzini, Daniele, Ferrara, Roberto, Brambilla, Marta, Occhipinti, Mario, Mazzeo, Laura, Provenzano, Leonardo, Spagnoletti, Andrea, Viscardi, Giuseppe, Sgambelluri, Francesco, Brich, Silvia, Miskovic, Vanja, Pedrocchi, Alessandra Laura Giulia, Trovo', Francesco, Manglaviti, Sara, Giani, Claudia, Ambrosini, Paolo, Leporati, Rita, Franza, Andrea, McCulloch, John, Torelli, Tommaso, Anichini, Andrea, Mortarini, Roberta, Trinchieri, Giorgio, Pruneri, Giancarlo, Torri, Valter, De Braud, Filippo, Proto, Claudia, Ganzinelli, Monica, Garassino, Marina Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254948/
https://www.ncbi.nlm.nih.gov/pubmed/37286305
http://dx.doi.org/10.1136/jitc-2023-006833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254948/
https://www.ncbi.nlm.nih.gov/pubmed/37286305
http://dx.doi.org/10.1136/jitc-2023-006833

Ejemplares similares